Randall Kaja
Corporate Officer/Principal chez International AIDS Vaccine Initiative, Inc.
Profil
Randall Kaja is currently a Partner at the International AIDS Vaccine Initiative, Inc. Prior to this, he worked at Pfizer Inc. from 1996 to 2011, where he held the position of Head-Clinical Operations in 2011.
Postes actifs de Randall Kaja
| Sociétés | Poste | Début |
|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Corporate Officer/Principal | 31/05/2011 |
Anciens postes connus de Randall Kaja
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |